Search

Displaying results 5891 - 5900 of 10000 in total
  1. Drug

    AVI-4020

    go.drugbank.com/drugs/DB05873
    Investigational

    AVI-4020 is a neugene antisense drug candidate for the treatment of patients with acute West Nile virus disease who have serious neurological impairment (WNV neuroinvasive disease).

  2. Drug

    Iratumumab

    go.drugbank.com/drugs/DB05550
    Investigational

    In phase I/II clinical trials for treatment of CD30+ lymphomas.

  3. Drug

    GSK-239512

    go.drugbank.com/drugs/DB15120
    Investigational

    GSK-239512 is under investigation in clinical trial NCT00474513 (An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.).

  4. Drug

    Fosmanogepix

    go.drugbank.com/drugs/DB15183
    Investigational

    Fosmanogepix is under investigation in clinical trial NCT03604705 (An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia).

  5. Drug

    Temelimab

    go.drugbank.com/drugs/DB15634
    Investigational

    Temelimab is under investigation in clinical trial NCT02782858 (Clinical Trial Assessing the HERV-W Env Antagonist Gnbac1 for Efficacy in MS).

  6. Drug

    EHC18

    go.drugbank.com/drugs/DB05114
    Experimental

    EHC18 is an immune regulation medicine. It is a broad spectrum of specific HCV proteins.

  7. Drug

    CX-046684

    go.drugbank.com/drugs/DB19414
    Approved

    CX-046684 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage KP.2. It is the active ingredient of the 2024-2025 formulation of Moderna's Spikevax vaccine.

  8. Drug

    AZX-100

    go.drugbank.com/drugs/DB06323
    Investigational

  9. Drug

    Denibulin

    go.drugbank.com/drugs/DB05932
    Experimental

    Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.

  10. Drug

    LY-517717

    go.drugbank.com/drugs/DB05713
    Investigational

    LY517717 is an investigational oral direct inhibitor of activated Factor Xa. It is believed to be Lilly's PMD-3112 (licensed from Amgen).